These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 19285266)

  • 1. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.
    Moreira FA; Grieb M; Lutz B
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):133-44. PubMed ID: 19285266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The psychiatric side-effects of rimonabant.
    Moreira FA; Crippa JA
    Braz J Psychiatry; 2009 Jun; 31(2):145-53. PubMed ID: 19578688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CB1 receptor antagonists: new discoveries leading to new perspectives.
    Kirilly E; Gonda X; Bagdy G
    Acta Physiol (Oxf); 2012 May; 205(1):41-60. PubMed ID: 22463610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A role for cannabinoid CB1 receptors in mood and anxiety disorders.
    Witkin JM; Tzavara ET; Nomikos GG
    Behav Pharmacol; 2005 Sep; 16(5-6):315-31. PubMed ID: 16148437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).
    Raffa RB; Ward SJ
    J Clin Pharm Ther; 2012 Jun; 37(3):260-5. PubMed ID: 21740450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists.
    Lazary J; Juhasz G; Hunyady L; Bagdy G
    Trends Pharmacol Sci; 2011 May; 32(5):270-80. PubMed ID: 21497918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
    González S; Fernández-Ruiz J; Di Marzo V; Hernández M; Arévalo C; Nicanor C; Cascio MG; Ambrosio E; Ramos JA
    Drug Alcohol Depend; 2004 May; 74(2):159-70. PubMed ID: 15099659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid receptor CB1 antagonists state of the art and challenges.
    Bifulco M; Santoro A; Laezza C; Malfitano AM
    Vitam Horm; 2009; 81():159-89. PubMed ID: 19647112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impairments in endocannabinoid signaling and depressive illness.
    Hill MN; Gorzalka BB
    JAMA; 2009 Mar; 301(11):1165-6. PubMed ID: 19293417
    [No Abstract]   [Full Text] [Related]  

  • 11. The endocannabinoid system: a promising target for the management of type 2 diabetes.
    Scheen AJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.
    Di Marzo V
    Pharmacol Res; 2009 Aug; 60(2):77-84. PubMed ID: 19559360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core.
    Schoffelmeer AN; Hogenboom F; Wardeh G; De Vries TJ
    Neuropharmacology; 2006 Sep; 51(4):773-81. PubMed ID: 16806307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
    Ward SJ; Raffa RB
    Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
    [No Abstract]   [Full Text] [Related]  

  • 15. [The endocannabinoid system].
    Sudano I; Périat D; Noll G
    Praxis (Bern 1994); 2008 Apr; 97(7):375-80. PubMed ID: 18548817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer.
    Wright KL; Robertson DA; Moyer MP; Ward SG
    Int J Cancer; 2008 Apr; 122(8):1920-1. PubMed ID: 18076045
    [No Abstract]   [Full Text] [Related]  

  • 17. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk.
    Rosenson RS
    Cardiology; 2009; 114(3):212-25. PubMed ID: 19641317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor.
    Cox ML; Haller VL; Welch SP
    Eur J Pharmacol; 2007 Sep; 570(1-3):50-6. PubMed ID: 17588560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rimonabant on weight and cardiometabolic risk factors.
    Gadde KM
    JAMA; 2006 Aug; 296(6):649-50; author reply 650-1. PubMed ID: 16896103
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.